Abnova (Taiwan) Corporation

Taiwan Stock Exchange 4133.TW

Abnova (Taiwan) Corporation Gross Profit Margin for the year ending December 31, 2023: 45.52%

Abnova (Taiwan) Corporation Gross Profit Margin is 45.52% for the year ending December 31, 2023, a -6.95% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Abnova (Taiwan) Corporation Gross Profit Margin for the year ending December 31, 2022 was 48.92%, a 11.92% change year over year.
Abnova (Taiwan) Corporation Gross Profit Margin for the year ending December 31, 2021 was 43.71%, a -6.55% change year over year.
Abnova (Taiwan) Corporation Gross Profit Margin for the year ending December 31, 2020 was 46.77%, a 4.52% change year over year.
Abnova (Taiwan) Corporation Gross Profit Margin for the year ending December 31, 2019 was 44.75%, a 2.85% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Taiwan Stock Exchange: 4133.TW

Abnova (Taiwan) Corporation

CEO	Yi Huang Huang
IPO Date	Dec. 28, 2009
Location	Taiwan
Headquarters	No. 108, Jhouzih Street
Employees	110
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.

Key trends

Past 5 years